drugset / Trial / NCT01712919
Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)
NaSingle-groupOpen-labelTreatment
Summary
The investigators will add weekly cetuximab (c225) to the standard care of chemoradiation against locoregionally advanced Nasopharyngeal Carcinoma (NPC), and evaluate the toxicity and efficacy of this new regimen.
Timeline
- Start
- 2010-05
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Background | Nedaplatin | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |